Search results
5 days ago · The liver is the primary site of metastasis in most patients, though uveal melanoma spreads widely in advanced disease. The only FDA approved immunotherapy medication for metastatic uveal melanoma is the HLA-A02:01 restricted bispecific T cell engager drug, Tebentafusp.
Jul 1, 2024 · In our study, we found that endothelial cells exhibit significant senescence during the metastasis of uveal melanoma, which may be associated with liver metastasis of uveal melanoma. Cellular senescence has an impact on tumor development and progress.
Jun 22, 2024 · Koch EAT, Petzold A, Wessely A, Dippel E, Eckstein M, Gesierich A, et al. Liver-directed treatment is associated with improved survival and increased response to immune checkpoint blockade in metastatic uveal melanoma: results from a retrospective multicenter trial.
6 days ago · Uveal melanoma (UM) is a rare malignancy where 50% of patients develop metastatic disease primarily affecting the liver. Approximately 40% of patients with metastatic UM respond to one-time isolated hepatic perfusion (IHP) with high-dose melphalan.
Jun 12, 2024 · Uveal melanoma (UM), a distinct subtype of melanoma, presents unique challenges in its clinical management due to its complex molecular landscape and tendency for liver metastasis. This review highlights recent advancements in understanding the molecular pathogenesis, genetic alterations, and immune ….
Jun 22, 2024 · This narrative review provides a timely and comprehensive overview of the current treatment landscape for metastatic UM. Uveal melanoma (UM) is genetically a distinct tumor compared to cutaneous melanoma (CM), and due to its low mutational burden, it is far less perceptible to the immune system.
Jun 12, 2024 · Uveal melanoma (UM), a distinct subtype of melanoma, presents unique challenges in its clinical management due to its complex molecular landscape and tendency for liver metastasis.
